Frontlight ResearchEarly access
Taking people in NetherlandsPhase 2
Tests OV329 in adults with epilepsy and photosensitive brain responses
Tests OV329 in adults with epilepsy and light-triggered brain wave changes.
Key facts
- Who runs it
- Ovid Therapeutics Inc.
- Where
- Leiden, NetherlandsSee the site
- Trial code
- Registry title
- OV329 Evaluation in Participants with Epilepsy and PPR
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 4 people, planned
- Started
- 7 Aug 2026
- Expected to end
- 31 Mar 2027
- Type of study
- Interventional
- Record updated
- 9 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 65 with epilepsy who show a repeatable abnormal brain-wave response to flashing light.
- Age
- 18 to 65 years
- Sex
- All sexes can join.
- Disease stage
- A diagnosis and history of epilepsy. A repeatable generalized brain-wave response to flashing light (photoparoxysmal response) of at least 4 points on a frequency scale at Screening and Baseline, in at least one eye condition.
- Earlier treatment
- People who take or took OV329 as extra therapy in the last 3 months cannot join, except in this study.
- Biomarker or test result
- A repeatable generalized photoparoxysmal response (PPR) on EEG, at least 4 points on a frequency scale, at Screening and Baseline.
Main reasons for not taking part
- History of non-epileptic seizures, such as metabolic or pseudo-seizures
- Classical juvenile myoclonus epilepsy with mostly early morning myoclonic seizures
- Taking or having taken OV329 as extra therapy within the last 3 months
- Known allergy to OV329 or possibly to one of its analogues
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Male or female participants aged 18 to 65 years at the time of consent
- Participants with a diagnosis and history of epilepsy (see exceptions in Exclusion Criteria)
- Participants with a reproducible IPS-induced generalized PPR of at least 4 points on a frequency assessment scale at Screening and Baseline in at least one eye condition
Who cannot take part
- Participants who are taking or have taken OV329 as concomitant therapy within the last 3 months, with the exception of this study
- Participants with a history of non-epileptic seizures (e.g., metabolic or pseudo-seizures)
- Participants with a diagnosis of Classical juvenile myoclonus epilepsy characterized by exclusively or predominantly early morning myoclonic seizures, as assessed by the investigator
- Participants with a known allergy to OV329 or potentially to one of its analogues
Where in Netherlands
- Centre for Human Drug ResearchLeiden, NetherlandsTaking people
About the trial
What the trial wants to find out
To evaluate the pharmacodynamic effect of OV329 on the IPS-induced PPR in participants with epilepsy.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Pharmacodynamic Evaluation of OV329 in Participants with Epilepsy and a Photo-Induced Generalized Epileptiform EEG-Response Phase 2 Proof-of-Concept.
- Plain-language title
- Tests OV329 in adults with epilepsy and photosensitive brain responsesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 10 November 2026.
- Record updated
- 9 November 2026